Amarante, I. et al. 2025. Full recovery over one year of the overlap syndrome scleromyositis to maintenance therapy with mycophenolate mofetil and rituximab, which relapsed within 8 months of discontinuation. European Journal of Case Reports in Internal Medicine. 12, 5 (May 2025). DOI:https://doi.org/10.12890/2025_005154.